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Aquaporin-2 (AQP2) is the vasopressin-regulated water channel that controls renal
water reabsorption and plays an important role in the maintenance of body water
homeostasis. Excessive glucocorticoid as often seen in Cushing’s syndrome causes
water retention. However, whether and how glucocorticoid regulates AQP2 remains
unclear. In this study, we examined the direct effect of dexamethasone on AQP2 protein
expression and activity. Dexamethasone increased AQP2 protein abundance in rat inner
medullary collecting duct (IMCD) suspensions. This was confirmed in HEK293 cells
transfected with AQP2 cDNA. Cell surface protein biotinylation showed an increase of
dexamethasone-induced cell membrane AQP2 expression and this effect was blocked
by glucocorticoid receptor antagonist RU486. Functionally, dexamethasone treatment
of oocytes injected with an AQP2 cRNA increased water transport activity as judged
by cell rupture time in a hypo-osmotic solution (66 ± 13 s in dexamethasone vs.
101 ± 11 s in control, n = 15). We further found that dexamethasone treatment
reduced AQP2 protein degradation, which could result in an increase of AQP2 protein.
Interestingly, dexamethasone promoted cell membrane AQP2 moving to less buoyant
lipid raft submicrodomains. Taken together, our data demonstrate that dexamethasone
promotes AQP2 protein expression and increases water permeability mainly via inhibition
of AQP2 protein degradation. The increase in AQP2 activity promotes water reabsorption,
which may contribute to glucocorticoid-induced water retention and hypertension.
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INTRODUCTION
Dexamethasone is a synthetic glucocorticoid that has been used clinically since the early
1960’s to treat a variety of conditions. A major adverse effect of dexamethasone treatment is
hypertension (Kalimi, 1989; Ferrari, 2003; Mangos et al., 2003; Li et al., 2008). However, the
underlying mechanism of dexamethasone-induced hypertension remains largely unknown. In
animal studies, administration of dexamethasone in the drinking water induces a rapid and
sustained elevation of blood pressure in wild-type mice (Zhang et al., 2009; Goodwin et al., 2010).
This effect is mediated via the glucocorticoid receptor and is independent of the mineralocorticoid
Chen et al. AQP2 regulation by dexamethasone
receptor (Zhang et al., 2009; Goodwin et al., 2010). Interestingly,
the dexamethasone-induced blood pressure increase is not
accompanied by an increase in total peripheral resistance (Ong
et al., 2009) and sodium retention (Ong et al., 2007).
The water channel aquaporin 2 (AQP2) expressed in the
apical membrane of the principal cells of renal collecting duct,
mediates water absorption, and plays a crucial role inmaintaining
water homeostasis in mammals (Moeller et al., 2010; Chen et al.,
2012). The global AQP2 knockout mice died within the first
few days of life (Rojek et al., 2006). The connecting tubule
specific AQP2 knockout mice have defective renal water handling
under basal conditions, with higher urine volumes and reduced
urine osmolality (Kortenoeven et al., 2013). Dysfunction of
AQP2 is linked to many water related diseases, such as central
and nephrogenic diabetes insipidus, chronic heart failure, and
nephrotic syndrome (Jaffuel et al., 2013). Arginine vasopressin
(AVP, also named antidiuretic hormone, ADH) is the major
hormone that regulates AQP2 activity in vivo (Saito et al., 2009;
Fenton et al., 2013). Vasopressin binds to the V2 vasopressin
receptor on the basolateral side of collecting duct principal
cells and activates a cAMP-dependent signal transduction
pathway. Acute regulation by vasopressin involves AQP2
phosphorylation and translocation from cytoplasmic vesicles
to the apical plasma membrane in the principal cells of the
collecting duct (Tamma et al., 2011; Radin et al., 2012), and the
subsequent increase in the water permeability of the epithelium.
Chronic vasopressin increases AQP2 protein abundance in the
collecting duct. AQP2 abundance is increased about 4–10-
fold after long-term increases in circulating vasopressin levels
(Radin et al., 2012).
A number of studies have shown that glucocorticoid
hormones modulate ion channels and transporter activities that
could regulate water balance and blood pressure. Dexamethasone
up-regulates ENaC (Sayegh et al., 1999) and CFTR (Caohuy
et al., 2009; Prota et al., 2012) expression at both transcriptional
and post-transcriptional levels. Dexamethasone increases the
transcript level and the membrane protein abundance of the
Na+/Ca2+ exchanger NCX3 (Heise et al., 2011). We and Schrier
showed downregulation of the urea transporter UT-A1 by
glucocorticoids (Klein et al., 1997; Naruse et al., 1997; Li et al.,
2008). Previous study from animal experiments showed that
dexamethasone significantly upregulated the expression of AQP2
in the inner medulla in adrenalectomized rats (Chen et al.,
2005). However, whether and how dexamethasone can directly
regulate AQP2 expression and water permeability in kidney inner
medullary collecting duct (IMCD) is still unknown.
To avoid the extra-renal environmental factors that might
influence the effects of dexamethasone on AQP2, in this study
we examined the role of dexamethasone on AQP2 protein
expression by using rat IMCD suspensions and HEK293 cells
transfected with an AQP2 cDNA. The functional effect of
dexamethasone on AQP2 was examined by using the oocyte
expression system. We found that dexamethasone increases
AQP2 expression in rat IMCD suspensions and in the cultured
HEK293 cells and increases AQP2 activity in Xenopus laevis
oocytes. This effect occurs mainly through inhibition of AQP2
protein degradation.
MATERIALS AND METHODS
Animal Experiments
Male Sprague-Dawley rats (Charles River Laboratories,
Wilmington, MA) weighing 200–300 g received free access
to water and standard rat chow. The rats were euthanized
by CO2 asphyxiation. Kidneys were removed and the inner
medulla (IM) was dissected. IMCD suspensions were prepared
by digestion with hyaluronidase and collagenase B (Sigma, St.
Louis, MO) as described before (Chen et al., 2011) and incubated
with DMEM supplemented with 10% fetal bovine serum (FCS),
25mM HEPES in a 5% CO2 incubator. The freshly prepared
suspensions were treated with dexamethasone (Sigma, D8893),
vasopressin (Sigma, V9879), or forskolin (Sigma, F3917) for the
indicated times and subjected to lipid raft isolation or protein
analysis by Western blot. All animal protocols were approved
by the Emory University Institutional Animal Care and Use
Committee.
Plasmid Construction
The rat AQP2 cDNA gene coding the full-length protein was
RT-PCR amplified from kidney IM mRNA. The primers were
designed based on the AQP2 gene (access number: NM 012909)
and a BamHI site was introduced in forward primer AQP2a:
5′-CGGGATCCGGAG CAGCATGTGGGAACTCAGATCC
-3′ and a XbaI site was added in reverse primer AQP2b:
GCTCTAGAGGGAGCTCAGGCCTTGCTGCCGCGAG. The
PCR amplified product was purified, digested with BamHI/XbaI
and subcloned into a mammalian expression vector pcDNA3
(pcDNA3-AQP2) or into an oocyte expression vector pGH19
(pGH19-AQP2). All of the constructs were verified by nucleotide
sequence analysis.
Cell Culture, Transient Transfection, and
Treatment
HEK293 cells were routinely cultured in DMEM supplemented
with 10% FCS at 37◦C in 5% CO2. Plasmids were transfected
by Lipofectamine 2000 (Invitrogen) according to the instruction
manual. The cells were treated with 0.1µM dexamethasone,
0.1µM RU486 (or mifepristone), 0.1µM vasopressin, or 10µM
forskolin for the indicated times. For the protein degradation
studies, the cells were incubated with 100µg/ml cycloheximide
(Sigma, C4859) and chased for up to 12 h.
Cell Surface Protein Biotinylation
Cell surface biotinylation assays were performed as described
before (Chen et al., 2006). Briefly, after treatment, the cells were
incubated twice with a freshly prepared solution of 1.0mg/ml
EZ-Link sulfo-N-hydroxysuccinimide disulfide-biotin (Pierce,
21331) in borate buffer for 30min at 4◦C. The biotin reaction
was quenched for 5min with 0.1mM lysine (Sigma, L5626).
After washing with PBS, the cells were lysed in a modified
radioimmuno-precipitation assay (RIPA) buffer (150mM NaCl,
10mM Tris.HCl, pH 7.5, 1mM EDTA, 1% Triton X-100, 1%
sodium deoxycholate, 0.1% SDS, and protease inhibitors). Equal
amounts of cleared lysate protein (0.5–1mg) were incubated
with 25µl of immobilized streptavidin-agarose beads (Pierce,
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20349) overnight at 4◦C with gentle shaking. The beads were
washed four times with RIPA buffer. Biotin-labeled proteins were
eluted in 35µl of Laemmli sample buffer and analyzed for AQP2
expression by Western blotting.
Cell Lysate Preparation and Western Blot
After treatment, the IMCD suspensions or HEK293 cells were
homogenized in a glass homogenizer in RIPA buffer. The
supernatants were collected after a brief centrifugation at
10,000 rpm for 10min at 4◦C. The protein concentration was
determined by the BCA Protein Assay (Thermo scientific 23223).
For Western blot analysis, the proteins were separated by 10%
or 4–15% SDS-PAGE and electrotransferred to polyvinylidene
difluoride (PVDF) membranes (Bio-Rad). The membranes were
routinely processed by blocking with 5% milk/PBST, incubation
with primary antibody overnight and with horseradish
peroxidase-conjugated secondary antibody for 1 h. Proteins
were detected using an Enhanced Chemiluminescence (ECL) Kit
(Amersham). The following antibodies were used: AQP2 (Kim
et al., 2003); UT-A1 (Chen et al., 2011); GAPDH (Santa Cruz,
sc-25778); secondary horseradish peroxidase-conjugated goat
anti-rabbit IgG (Amersham, NA934). The Western blot signals
were quantified using the NIH ImageJ program. The intensity of
AQP2 was normalized to GAPDH and expressed as a percentage
compared with the value in controls (100%).
Oocyte Isolation, cRNA Preparation and
Microinjection, Biotinylation and Water
Permeability Experiments
Xenopus laevis oocytes were prepared and maintained in OR3
medium as described previously (Chen et al., 2011). Capped
AQP2 cRNAs were transcribed from linearized pGH19-AQP2
with T7 polymerase using the mMESSAGE mMACHINE T7
Ultra Kit (Ambion). Two ng of AQP2 cRNAs were injected into
oocytes. After 3 days, good and healthy oocytes were selected
for protein expression and functional measurements. Some cells
were treated with 0.1µM dexamethasone for 2 days. UT-A1
cRNAs (Chen et al., 2011) were also injected and used as a
control. Oocyte biotinylation was performed as before (Feng
et al., 2009). Oocyte water permeability was measured by placing
oocytes in a low osmotic solution (one volume of ND96 mixed
with one volume of water), and the time to cell rupture in the
hypo-osmolarity solution was counted by visual inspection using
a microscope.
Isolation of Lipid Rafts from IMCD
IMCD lipid raft fractionations were performed with a 5–40%
sucrose discontinuous gradient as reported previously (Chen
et al., 2011). Briefly, after dexamethasone treatment, rat IMCD
suspensions were homogenized in 0.5% Brij 96V (Sigma)/TNEV
buffer (10mM Tris-HCl pH 7.5, 150mM NaCl, 5mM EDTA,
2mM Na vanadate, and protease inhibitor cocktail) on ice for
30min. The supernatants were collected and mixed with 80%
sucrose by 1:1 volume. The sucrose gradient was built by layering
on the top with 35 and 5% sucrose and then centrifuged in a SW
50.1 rotor (BeckmanCoulter) at 34,000 rpm (∼110,000 g) for 16 h
at 4◦C. Equal sizes of fractions (∼400µl) were collected from the
top to bottom and analyzed by Western blot.
Statistical Analysis
All values were expressed as means ± SD. Statistical analysis
of the data was performed by One-Way ANOVA followed by
Tukey’s HSD test. Differences were considered as significant at
P < 0.05.
RESULTS
Dexamethasone Increases AQP2 Protein
Abundance in Rat IMCD
To investigate the direct effect of dexamethasone on AQP2
protein expression in kidney IM, freshly prepared IMCD
suspensions were exposed to 0.1µM dexamethasone for 6 h.
IMCD pellets were then lysed in RIPA buffer. Equal amounts
of cell lysate were immunoblotted with antibodies to AQP2
and GAPDH. Western blot signals were quantified by NIH
ImageJ. Kidney AQP2 shows a narrow 29 kDa band and 35–
50 kDa diffuse bands. Densitometry quantification included both
forms. Figure 1A shows that dexamethasone treatment increases
total AQP2 protein abundance (p < 0.05, n = 4). Since
vasopressin upregulates AQP2 (Hasler et al., 2002; Nedvetsky
et al., 2010), we also treated IMCD suspensions with vasopressin
and adenylyl cyclase stimulator forskolin. Figure 1B shows
that dexamethasone, as well as vasopressin and forskolin,
upregulated AQP2 protein expressions. Urea transporter UT-
A1 is another important transporter expressed in kidney IMCD
and is regulated by vasopressin. Early studies by us and Schrier
et al. showed that glucocorticoid (dexamethasone) treatment
downregulates UT-A1 protein expression (Klein et al., 1997;
Naruse et al., 1997; Li et al., 2008). The same samples were
examined for UT-A1 protein expression. Unlike upregulating
AQP2, dexamethasone treatment caused a decrease of UT-A1
protein abundance. Native UT-A1 from kidney presents two
glycosylation forms of 97- and 117-kDa bands. Both bands were
included in the densitometry analysis.
Dexamethasone Upregulates AQP2
Expression in the Transfected HEK 293
Cells
To further evaluate the influence of dexamethasone on AQP2
protein expression, we used HEK293 cells transiently transfected
with pcDNA3-AQP2 cDNA. Forty-eight h after transfection,
cells were incubated with 0.1µM dexamethasone for 6 h. As
observed in rat IMCD suspensions, dexamethasone treatment
increased AQP2 protein abundance by ∼63% (p < 0.01, n = 3)
(Figure 2A). The time course studies revealed that the effect of
dexamethasone on AQP2 protein expression started as early as
2 h after treatment (Figure 2B).
Dexamethasone Increases AQP2 Cell
Membrane Expression
To examine whether dexamethasone treatment could increase
AQP2 cell membrane abundance, cell surface protein
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FIGURE 1 | Dexamethasone (Dex) treatment increases AQP2 protein
abundance in rat IMCD. (A) Rat IMCD suspensions were exposed to
0.1µM Dex for 6 h and lysed in RIPA buffer. Equal amounts of
supernatant were immunoblotted with antibodies to AQP2 and GAPDH.
(B) Rat IMCD suspensions were exposed to 0.1µM AVP, 10µM
forskolin (FSK) or 0.1µM Dex. Equal amounts of lysates were
immunoblotted with antibodies to AQP2, UT-A1, and GAPDH. Western
blot signals were quantified by NIH ImageJ (compared to control,
*P < 0.05, **P < 0.01, n = 3).
biotinylation was carried out. Figure 3 shows an increase
of dexamethasone-induced cell membrane AQP2 expression.
To investigate whether this effect is mediated through the
glucocorticoid receptor, some cells were pre-treated with
0.1µM glucocorticoid receptor antagonist RU486 (Ogata et al.,
2001) for 30min, then treated with dexamethasone. RU486
blocked total and cell membrane AQP2 abundance induced by
dexamethasone.
Dexamethasone Increases AQP2 Activity in
Oocytes
To assess whether the increased AQP2 protein expression
following treatment by dexamethasone correlates with a
functional change in water transport, AQP2 was expressed
in oocytes. AQP2 water transport activity was measured by
counting cell rupture time when the cells were switched from
200mOsm to a hypo-osmotic solution of 100mOsm. The average
cell rupture time for the water-injected control oocytes is about
FIGURE 2 | Dexamethasone increases AQP2 expression in the
transfected HEK 293 cell. (A) HEK293 cells were grown in 6-well plates and
transfected with pcDNA3-AQP2 1.0µg for 48 h. After incubation with 0.1µM
Dex for 6 h, cells were collected and solubilized in RIPA buffer. Equal amounts
of proteins in the supernatant were analyzed by immunoblotting with AQP2
and GAPDH antibodies (n = 4). (B) Time course experiment. HEK293 cells
were transfected with pcDNA3-AQP2 1.0µg for 48 h then treated by 0.1µM
Dex for the indicated time. AQP2 protein expression was analyzed by
immunoblotting with AQP2 antibody. Western blot signals were quantified by
NIH ImageJ (compared to control, **P < 0.01, n = 4).
4675.2 ± 216.7 s (n = 15). The cell rupture time for the cells
injected by AQP2 is 101.2 ± 11 s (n = 15). We also injected
UT-A1 cRNA as a control. Although the average rupture time
for UT-A1 injected oocytes was 2920.8 ± 67.4 s (n = 15), much
longer than that of AQP2 injected oocytes, it is significantly
shorter than that in water-injected oocytes (p < 0.01), indicating
that UT-A1 somehow weakly moves water (Figure 4A). The
water permeability experiment in Figure 4B showed that the cell
rupture time in the dexamethasone-treated AQP2 cells was 65.8
± 13.5 s shorter than that in the untreated AQP2 cells 101.2
± 11 s (P < 0.01, n = 15), indicating that dexamethasone
treatment increases AQP2 activity. AQP2 protein expression
was examined by biotinylation and western blot. Compared
to the untreated AQP2 cRNA injected cells, the total and cell
membrane AQP2 protein were all increased by dexamethasone
(Figure 4C).
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FIGURE 3 | Dexamethasone increases AQP2 cell membrane
expression. HEK293 cells were grown in 6-well plates and transfected with
pcDNA3-AQP2 1.0µg for 48 h. After incubation with Dex or 0.1µM RU486
pre-treatment 30min + Dex for 6 h, cells were processed for cell membrane
protein biotinylation and lysed in RIPA buffer. The biotinylated proteins were
collected by streptavidin beads. Cell membrane AQP2 was analyzed by
immunoblotting with AQP2 antibody. Western blot signals were quantified by
NIH ImageJ (compared to control, **P < 0.01, n = 4).
Dexamethasone Reduces AQP2
Degradation
To address the possible mechanism by which dexamethasone
upregulates AQP2, we investigated AQP2 degradation mediated
by dexamethasone. AQP2 HEK293 cells were pre-treated with
cycloheximide (CHX) to inhibit new protein synthesis. AQP2
protein degradation was assessed in the presence or absence
of dexamethasone. Comparing with non-dexamethasone-treated
control cells, AQP2 degradation was significantly reduced
with dexamethasone treatment (Figure 5). This suggests that
dexamethasone increases AQP2 level, at least partially, by
decreasing AQP2 degradation.
Dexamethasone Changes AQP2
Distribution in Lipid Rafts
We previously reported that AQP2 is localized in cell membrane
lipid raft submicrodomains (Feng et al., 2009). Many membrane
proteins’ apical sorting is determined by their association with
lipid rafts (Simons and Ikonen, 1997; Brown and London, 1998).
We treated IMCD suspensions with dexamethasone for 6 h
and then examined whether dexamethasone could alter AQP2
distribution in lipid rafts. Caveolin-1 was used as a positive
control for lipid raft fractions (Feng et al., 2009). Interestingly,
dexamethasone treatment increased AQP2 movement into less
buoyant lipid raft fractions 1∼2 (Figure 6).
DISCUSSION
Glucocorticoid hormones affect body water homeostasis (Ferrari,
2003). Many ion channels and transporter, such as ENaC (Sayegh
et al., 1999), CFTR (Caohuy et al., 2009; Prota et al., 2012), NCX3
(Heise et al., 2011), and UT-A1 (Naruse et al., 1997; Li et al.,
2008), are regulated by glucocorticoids. In kidney, glucocorticoid
FIGURE 4 | Dexamethasone treatment increases AQP2 protein
expression and water permeability in oocytes. Oocytes were injected with
cRNA encoding AQP2 (2 ng/23 nl/cell) or UT-A1 (2 ng/23 nl/cell). Control cells
were injected with the same amount of water. Some AQP2 injected oocytes
were incubated with 0.1µM dexamethasone for 48 h. (A,B) The water
permeability was measured by counting cell rupture time in a hypo-osmotic
solution (**P < 0.01, n = 15). (C) AQP2 protein expression. Oocytes (n = 15)
were processed for cell surface biotinylation. Total and biotinylated AQP2 were
examined by western blot with AQP2 antibody. Kidney IM tissue was used as a
positive control.
receptor expression is found along the entire nephron including
collecting duct epithelial cells (Ackermann et al., 2010), where
the AQP2 is located. However, the influence of glucocorticoid
hormones on AQP2 regulation is undetermined. Different
groups report different results; some are even contradictory
(Saito et al., 2000, 2009; Klein et al., 2006; Li et al., 2008).
Previous investigations of dexamethasone on AQP2 are largely
from in vivo studies. Obviously multiple factors may directly
or indirectly affect AQP protein expression and activity, which
add to the difficulty of evaluating the role of dexamethasone on
AQP2 regulation. Therefore, the direct effects of glucocorticoid
(dexamethasone) on AQP2 could be shadowed or influenced by
secondary physiologic changes that occur in vivo. For example,
in an in vivo study, dexamethasone at dose of 100µg/100 g
body wt causes hyperglycemia and glucosuria, which could also
impair urinary dilution and concentration (Li et al., 2008).
Dexamethasone treatment increases urine flow rate, urinary
sodium excretion, and urinary urea excretion (Li et al., 2008).
Glucocorticoids activate the serum glucocorticoid kinase 1
(SGK1) gene, which regulates sodium transporters, leading to
hypertension (Vallon and Lang, 2005). The global effect of
dexamethasone might explain why different groups observe
different, or even contradictory, results of AQP2 regulation by
dexamethasone when using different animal models (Saito et al.,
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FIGURE 5 | Effect of dexamethasone on AQP2 stability. HEK293 cells
were transfected with pcDNA3-AQP2. After 48 h, the cells were pre-treated
with CHX (100µg/ml) for 30min, then treated without or with dexamethasone
(0.1µM) for the indicated time. Total AQP2 protein was analyzed by western
blot. Protein signals were quantified by NIH ImageJ (compared to CHX,
*P < 0.05, **P < 0.01, n = 3).
2000, 2009; Chen et al., 2005; Klein et al., 2006). To specifically
focus on the direct effect of dexamethasone on AQP2, in the
current study, we used rat IMCD suspensions and treated them
with dexamethasone. Our study clarified an important dispute
and showed that dexamethasone upregulates AQP2 protein
expression. This conclusion was further confirmed in HEK293
cells transfected with an AQP2 cDNA.
AQP2 is the vasopressin-sensitive water channel and
vasopressin enhances AQP2 protein abundance (Hasler et al.,
2002; Nedvetsky et al., 2010). Consistently, our data in Figure 1A
show that vasopressin, as well as the adenylyl cyclase stimulator
forskolin, upregulate AQP2 protein expression. This prompted
us to ask whether dexamethasone upregulates AQP2 through an
increase of vasopressin and/or the PKA pathway. However, it
is unlikely that dexamethasone increases AQP2 by vasopressin
in vivo. Both animal and human studies have demonstrated
that synthesis and release of arginine vasopressin are actually
suppressed by exogenous administration of glucocorticoid
hormone under normal conditions and are increased in
glucocorticoid deficiency (Raff, 1987; Biewenga et al., 1991;
Toftegaard and Knudsen, 1995; Batalhão et al., 2008; Saito et al.,
2009; Coiro et al., 2011). This suggests that glucocorticoids may
have a direct effect on AQP2 and increase its expression.
Glucocorticoids are the hormones that generally promote
protein catalysis and protein ubiquitination (Debigaré and Price,
2003; Sun et al., 2008). Despite the downregulation effect of
FIGURE 6 | Effect of dexamethasone on AQP2 lipid raft distribution.
Kidney IMCD suspensions were treated with/without 0.1µM dexamethasone
for 6 h then processed for lipid raft isolation by a 5–40% sucrose gradient
ultracentrifugation. Equal sizes of fractions (∼400µl) were collected from the
top to bottom and analyzed by Western blot with AQP2 and caveolin-1
antibodies (n = 3).
dexamethasone on protein abundance, studies also show that
dexamethasone can increase the expression of some proteins
(Martinho et al., 2012; Laste et al., 2013; Nostramo et al., 2013).
Our group has worked on kidney urea transporter UT-A1 for
many years. We find that dexamethasone treatment decreases
UT-A1 expression (Klein et al., 1997; Naruse et al., 1997). UT-
A1 shares many of the same regulatory mechanisms as AQP2.
Both UT-A1 and AQP2 are expressed in the kidney IM and are
vasopressin sensitive targets. However, the protein abundance
of UT-A1 and AQP2 sometimes change differently (Bou Matar
et al., 2012). In fact, our initial desire was to investigate
the mechanism of how dexamethasone downregulates UT-A1.
Interestingly, opposite to the effect of dexamethasone on UT-
A1, we found that dexamethasone treatment markedly increases
AQP2 protein abundance in kidney IMCD (Figure 1) as well as in
HEK293 cells transfected with AQP (Figure 2). This is consistent
with Kortenoeven’s finding that dexamethasone treatment
increases AQP2 protein abundance in mouse collecting duct
(mpkCCD) cells transfected with AQP2 (Kortenoeven et al.,
2012). We further confirmed that the effect of dexamethasone
on AQP2 protein expression is mainly dependent on the
glucocorticoid receptor (Figure 3).
Protein degradation is an important mechanism by which
cells regulate the levels of cellular proteins (Ciechanover, 2005).
Both lysosomal and proteasomal degradation are involved in
AQP2 protein degradation (Hasler et al., 2002; Nedvetsky
et al., 2010; Kortenoeven et al., 2012). Treatment with a
PKC stimulator induces AQP2 ubiquitination and lysosomal
degradation (Tamma et al., 2011; Moeller et al., 2014). Inhibition
of the lysosome by chloroquine inhibits AQP2 degradation
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(Kamsteeg et al., 2006; van Balkom et al., 2009; Kortenoeven
et al., 2012). A study by Nedvetsky et al. showed that AQP2
also undergoes polyubiquitination and proteasome mediated
protein degradation (Nedvetsky et al., 2010). Vasopressin
activates cAMP-PKA and inhibits p38-mitogen-activated protein
kinase (p38-MAPK). Inhibition of p38-MAPK is associated
with decreased AQP2 polyubiquitination and proteasomal
degradation, therefore leading to increasing AQP2 protein
abundance (Nedvetsky et al., 2010). In the current study, we
found that dexamethasone reduces the degradation of AQP2.
Thus, we propose that dexamethasone increases the level of
AQP2, at least partially, by reducing the degradation of AQP2.
Kortenoeven et al. recently reported that prostaglandins reduce
the dDAVP-induced AQP2 abundance and this effect can be
prevented by lysosome inhibitor. Dexamethasone downregulates
COX2 expression and prostaglandin synthesis (Kortenoeven
et al., 2012). At least one mechanism of dexamethasone-
upregulated AQP2 protein levels could be through inhibition
of prostaglandin-induced AQP2 lysosomal degradation. Further
study is required to elucidate whether inhibition of a proteasomal
pathway is also involved and whether it is mediated by protein
ubiquitination.
Another interesting finding in this study is that
dexamethasone increases AQP2 distribution in lipid raft
microdomains on the cell membrane. The physiological
significance of this change is currently not known. Lipid rafts
have been implicated in the regulation of membrane proteins in
many aspects, such as protein trafficking, stability and bioactivity
(Simons and Ikonen, 1997; Lingwood et al., 2009; Chen et al.,
2011). It is not clear from this study whether AQP2 moving
into lipid rafts will increase AQP2 protein stability and lead
to increased protein membrane abundance or the increased
AQP2 accumulation in lipid rafts is associated with enhanced
AQP2 function. Future studies will be required to address these
interesting questions.
In summary, glucocorticoid hormones are important
hormones that regulate body water homeostasis. Although
several groups have engaged in pursuing this question,
whether this hormone could influence water channel AQP2 is
inconclusive. Our ex vivo study using kidney IMCD suspensions,
as well as heterogeneously expressed AQP2 in HEK293 cells
and oocyte expression system, showed that dexamethasone
directly upregulates AQP2 protein expression. Dexamethasone
promotes AQP2 protein expression mainly by inhibiting AQP2
degradation. We conclude that glucocorticoid hormones may
participate in the regulation of body water balance by increasing
AQP2 expression.
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